Chronic Atrophic Gastritis
Conditions
Keywords
Chronic Atrophic Gastritis, Modified Liujunzi Decoction, Treatment Based on Syndrome Differentiation, Clinical Study, Efficacy, Cohort Study
Brief summary
This is an observational cohort study of clinical efficacy study.The purpose of this topic is to evaluate the efficacy and safety of Modified Liujunzi Decoction based on syndrome differentiation in patients with chronic atrophic gastritis(CAG) after HP eradication.Taking Modified Liujunzi Decoction as the observation group and Weifuchun routine treatment as the control group, so as to provide evidence for the treatment of CAG and reduce the risk of gastric cancer. A total of 284 patients were included. The curative efficacy, symptom score and adverse events will be recorded and analyzed.
Interventions
DRUGMLD
Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
DRUGWFC
Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
Sponsors
Peking University First Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with CAG diagnosed by endoscopy and pathological examination, the pathological diagnosis criteria refer to the China consensus of chronic gastritis (2017) ; * Previous HP infection, HP negative after standardized treatment; * TCM syndrome differentiation mainly focuses on the weakness of the spleen and stomach,referring to the consensus on the diagnosis and treatment of chronic atrophic gastritis with integrated traditional Chinese and Western Medicine (2017), there is no restriction on concurrent syndrome; * Age 18-70 years old, regardless of gender; * The subject (or legal representative) voluntarily agreed and signed the informed consent form, and was able to abide by the study protocol during the study.
Exclusion criteria
* History of gastric surgery; * Combined with serious diseases affecting the study evaluation, such as serious liver disease, heart disease, kidney disease, malignant tumor and alcoholism; * Allergic to the drugs used in this study; * Participated in clinical research of other drugs in the first 3 months of the study; * Patients can't express correctly their subjective feelings and can't cooperate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Therapeutic effectiveness of gastric mucosal lesions | Half a year,a year | Referring to the CAG of the Guidelines for Clinical Research on New Chinese Medicines (2002), the effective treatment of gastric mucosal lesions is defined as the pathological score decreased by 1 point compared with the previous point. The effective rate of gastric mucosal lesions treatment = the number of cases with a decrease of ≥ 1 point by the previous score / the total number of cases × 100%. The effective rate of gastric mucosal lesions from different category will be calculated: respectively for atrophy, chronic inflammation, activity, intestinal metaplasia, and intraepithelial neoplasia . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The efficacy of OLGA,OLGIM | Half a year,a year | The efficacy of OLGA staging: OLGA staging decreased by ≥1 stage compared with the baseline is considered as effecacy.The effective rate = the number of cases with ≥1 stage decreased compared with the previous stage/the total number of cases × 100%. The efficacy of OLGIM staging:The OLGIM staging decreased by ≥1 stage from the baseline is considered effective for patients with intestinal metaplasia. The effective rate = the number of cases staging decreased by ≥ 1 stage compared with the previous stage /the total number of cases × 100% |
| Changes in clinical symptom scores | The third month,half a year ,the ninth month,a year. | Evaluate referring to the symptom grading and quantification standard of Guidelines for Clinical Research on Chronic Atrophic Gastritis from Guidelines for Clinical Research on New Chinese Medicines (2002).According to the clinical symptom severity assign different points. No, mild, moderate and severe symptoms are recorded as 0, 1, 2, and 3 point respectively. Record the changes of the symptom score at 6 months and 12 months compared with the baseline and evaluate . The calculation formula is the total score after treatment-the score in baseline . |
| The recurrence of HP | Half a year,a year | 13C-UBT was performed to determine HP, and the DOB value more than 4 is defined as the recurrence of HP. |
Countries
China
Contacts
Primary ContactQiuyue Huang, doctor
Outcome results
None listed